France Measles, Mumps, and Rubella Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Type (Monovalent, Trivalent (combined MMR), Tetravalent, and Others), By Target Population (Infants & Children and Adults), By Distribution Channel (Hospitals & Healthcare Institutions, Vaccine Centers & Public Health Clinics, Pediatric & Private Healthcare Clinics, and Others), and France Measles, Mumps, and Rubella Vaccines Market Insights, Industry Trend, Forecasts to 2035

France Measles, Mumps, and Rubella Vaccines Market Insights Forecasts to 2035

• The France Measles, Mumps, and Rubella Vaccines Market Size Was Estimated at USD 58.97 Million in 2024
• The France Measles, Mumps, and Rubella Vaccines Market Size is Expected to Grow at a CAGR of Around 8.89% from 2025 to 2035
• The France Measles, Mumps, and Rubella Vaccines Market Size is Expected to Reach USD 150.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, The France Measles, Mumps, And Rubella Vaccines Market Size is anticipated to reach USD 150.5 Million by 2035, Growing at a CAGR of 8.89% from 2025 to 2035. The France measles, mumps, and rubella vaccines market is driven by mandatory childhood vaccination, strong government support, and the need to prevent disease outbreaks. Rising measles cases, high public awareness, and the use of combined vaccines also increase demand across the country.

Market Overview

The France measles, mumps, and rubella (MMR) vaccines market is the market for triple vaccines that are used to prevent the three diseases, measles, mumps, and rubella, in France. The French MMR vaccine market includes developing, manufacturing, and distributing MMR vaccines as well as their administration in both public and private healthcare settings. The market is influenced by factors such as national immunization programs, mandatory vaccination policies, increasing concerns about measles outbreaks, high public awareness of the benefits of vaccines, and national efforts to sustain high immunization coverage and eliminate vaccine-preventable diseases.

The France measles, mumps, and rubella (MMR) vaccines market is primarily influenced by public health demands. Firstly, although there have been some advancements, the MMR coverage in France historically has been around the low 90s; thus, several communities have not reached the 95% immunization level necessary for herd immunity, thereby leading to periodic outbreaks and continuously retaining the demand for MMR vaccination. As a measure, France rolled out an extended mandatory vaccination policy in 2018, which included measles, mumps, and rubella (MMR) vaccines for all children going to school and daycare, thus securing a wider uptake and signalling the government's determination to eliminate these diseases.

The government also helps this market by financing national immunization programs and health promotion initiatives out of the overall health budgets. For instance, between 2018 and 2022, about EURO 400 million of public health funds were earmarked for promotional health and preventive efforts, which included campaigns for higher vaccination uptake, monitoring, and education to raise coverage and reduce inequalities. The MMR vaccines are covered by France’s national health insurance funds and public schemes at no charge to patients, thus enhancing demand and market stability through the elimination of financial barriers to vaccination.

Report Coverage

This research report categorizes the market for the France measles, mumps, and rubella vaccines market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France measles, mumps, and rubella vaccines market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France measles, mumps, and rubella vaccines market.

Driving Factors

The France measles, mumps, and rubella (MMR) vaccines market is driven by mandatory childhood vaccination policies, highly effective government immunization programs, and the need to prevent recurring measles outbreaks. Free access to MMR vaccines through universal healthcare coverage, increasing public awareness, incorporation into routine child health schedules, and conformity with WHO and EU disease elimination targets are also factors that contribute to continual market demand.

Restraining Factors

The market for measles, mumps, and rubella (MMR) vaccines in France is restrained by several challenges, such as vaccine hesitancy and misinformation. Access and adherence are further impacted by socio-economic and regional disparities, whereas public distrust as a result of past vaccine scandals continues to affect people's perceptions. Besides that, shortage of supply, bureaucratic sluggishness, and dependence on public procurement pricing can all restrict market growth even if the government is strongly supportive.

Market Segmentation

The France measles, mumps, and rubella vaccines market share is classified into type, target population, and distribution channel.

• The trivalent (combined MMR) segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France measles, mumps, and rubella vaccines market is segmented by type into monovalent, trivalent (combined MMR), tetravalent, and others. Among these, the trivalent (combined MMR) segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The trivalent (combined MMR) segment is growing because it offers simultaneous protection against measles, mumps, and rubella in a single dose, reducing the number of injections and clinic visits required. Strong government preference for combined vaccines, inclusion in France’s mandatory childhood immunization schedule, high clinical effectiveness, better patient compliance, and cost-efficiency for public health programs have made trivalent MMR vaccines the standard choice across France, driving their dominant revenue share and continued growth.

• The infants & children segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France measles, mumps, and rubella vaccines market is segmented by target population into infants & children and adults. Among these, the infants & children segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The infants & children segment is growing because MMR vaccination is mandatory in France’s childhood immunization schedule, with doses administered at early ages to prevent disease outbreaks. High birth rates relative to adult catch-up demand, strong government-funded vaccination programs, free vaccine access, and routine pediatric checkups ensure higher coverage and sustained growth in this segment.

• The vaccine centers & public health clinics segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France measles, mumps, and rubella vaccines market is segmented by distribution channel into hospitals & healthcare institutions, vaccine centers & public health clinics, pediatric & private healthcare clinics, and others. Among these, the vaccine centers & public health clinics segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The vaccine centers & public health clinics segment is growing because most MMR vaccines in France are given through government-run clinics, which provide free vaccines, reach many children, and run large vaccination programs, making them the main source of immunization.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France measles, mumps, and rubella vaccines market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Merck & Co., Inc.
• GlaxoSmithKline plc (GSK)
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Biological E. Limited
• Sinovac Biotech Ltd.
• Shanghai Institute of Biological Products
• Beijing Institute of Biological Products
• Indian Immunologicals Limited
• Zydus Lifesciences Limited
• Takeda Pharmaceutical Company Limited
• Valneva SE
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France measles, mumps, and rubella vaccines market based on the below-mentioned segments:

France Measles, Mumps, and Rubella Vaccines Market, By Type

• Monovalent
• Trivalent (combined MMR)
• Tetravalent
• Others

France Measles, Mumps, and Rubella Vaccines Market, By Target Population

• Infants & Children
• Adults

France Measles, Mumps, and Rubella Vaccines Market, By Distribution Channel

• Hospitals & Healthcare Institutions
• Vaccine Centers & Public Health Clinics
• Pediatric & Private Healthcare Clinics
• Others